Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘MAGE-A3’

We have heard much hullabaloo about adoptive T cell therapy approaches with tumour infiltrating lymphocytes (TILs) and chimeric antigen receptor (CAR) T cell therapies, but what about T cell receptor (TCR) therapy?

Over the last couple of years, various experts we have interviewed have alluded to TCR approaches in the pipeline that they have been involved in or come across, but this is not a topic we have covered in-depth as we, like many other observers, have been on the sidelines waiting for solid clinical data to mature.

Source: Adaptimmune

That time finally came around at ASCO last month, where we had the opportunity to discuss an NY-ESO–1 based TCR with one of the companies in this space, namely Adaptimmune.

We also covered several other constructs they have in their pipeline.

Inevitably there have been quite a few R&D setbacks with some of the TCR approaches evaluated, going back to Dr Steven Rosenberg and the NIH experiments back in the 1990’s with MART–1 as a target.

I was therefore really intrigued to find out more about how are Adaptimmune faring, what technical and clinical challenges remain, where are the programs going, and what have we learned so far?

To learn more from our latest thought leader interview and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Lindt Gold BunnyWhat questions are BSB readers sending in to us this month?

I wanted to take a moment out of AACR Previews and catch up on some recent news that is intriguing or perplexing subscribers. All questions are anonymous and in many cases, the same questions were actually sent in by multiple people, a testament to what’s top of mind in oncology lately.

Today, we cover a Q&A on a variety of topics on Kite Pharma (the Genentech collaboration and their TCR in solid tumours), a discussion about EGVRvIII in glioblastoma, and Gilead’s woes with idelalisib and an IO pipeline.

So let’s get started – subscribers can sign-in…

This content is restricted to subscribers

Free Email Updates
Subscribe to new post alerts, offers, and additional content!
We respect your privacy and do not sell emails. Unsubscribe at any time.
error: Content is protected !!